Login to Your Account

Clinic Roundup

Monday, March 28, 2011
Janssen Pharmaceutica NV, a subsidiary of New Brunswick, N.J.-based Johnson & Johnson, said data from an independent prospective study showed that treatment with Risperdal Consta (risperidone long-acting injection) was associated with a lower risk of hospitalization in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription